22 August 2019

In Targeted Oncology, Annelieke Willemsen, Carla van Herpen and colleagues, showed that  pulmonary function test with  diffusion capacity of the lungs for carbon monoxide and serum biomarkers (including SP-D and YKL-40) can be of aid to differentiate everolimus-related interstitial lung disease from other respiratory problems. . Change in DLCOc differentiated ILD from alternative diagnoses with 0.91 sensitivity and 0.78 specificity. Serum SP-D and YKL-40 could differentiate ILD from alternative diagnoses with 0.83 and 0.83 sensitivity, and 0.85 and 0.62 specificity, respectively. Prospective monitoring of DLCOc in combination with measurement of serum SP-D and YKL-40 appear useful to discriminate ILD from other causes of respiratory symptoms. 

This study shows that everolimus-related ILD occurs frequently. Prospective monitoring of DLCOc in combination with measurement of serum SP-D and YKL-40 appear useful to discriminate ILD from other causes of respiratory symptoms. 

Abstract

Background
Everolimus-related interstitial lung disease (ILD) (also: pneumonitis) poses a difficulty for physicians, as it is hard to discriminate ILD from other causes of respiratory symptoms and to decide on safe treatment continuation.

Objective
We investigated the capability of pulmonary function tests (PFT), plasma biomarkers, everolimus pharmacokinetics, and FDG-PET to discriminate between everolimus-related ILD and other causes of respiratory problems and to predict the severity of ILD.

Patients and methods
Women starting treatment with everolimus plus exemestane for advanced breast cancer were included. At baseline and during the first 3 months, respiratory symptoms, PFT with diffusion capacity of the lungs for carbon monoxide corrected for hemoglobin (DLCOc) and forced vital capacity, serum plasma biomarkers (including SP-D and YKL-40), everolimus trough concentration, and 18F-FDG-PET were prospectively recorded.

Results
Twenty-seven (out of 29 included) patients were evaluable for analysis. Fifteen patients (56%) developed everolimus-related respiratory signs or symptoms and four patients (15%) needed everolimus discontinuation and received corticosteroids. Change in DLCOc differentiated ILD from alternative diagnoses with 0.91 sensitivity and 0.78 specificity. Decrease in DLCOc (non-significant) was greatest in patients who needed everolimus discontinuation. Serum SP-D and YKL-40 could differentiate ILD from alternative diagnoses with 0.83 and 0.83 sensitivity, and 0.85 and 0.62 specificity, respectively. 18F-FDG-PET abnormalities did not precede clinical symptoms. No relationship between ILD and everolimus trough concentration was found.

Conclusions 
This study shows that everolimus-related ILD occurs frequently. Prospective monitoring of DLCOc in combination with measurement of serum SP-D and YKL-40 appear useful to discriminate ILD from other causes of respiratory symptoms. Clinicaltrials.gov identifier: NCT01978171.
 

Publication

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.
Willemsen AECAB, Tol J, van Erp NP, Jonker MA, de Boer M, Meek B, de Jong PC, van Moorsel C, Gerritsen WR, Grutters JC, van Herpen CML.

Annelieke Willemsen and Carla van Herpen are members of theme Rare cancers.


 

Related news items


KWF grant for better selection of individuals and lung nodules in lung cancer screening

1 November 2021

The Dutch Cancer Society has awarded the consortium project ‘Multi-source data approach for Personalized Outcome Prediction in lung cancer screening’ with a grant of 1,425,000 Euro. Colin Jacobs will lead the work package on using artificial intelligence for accurate risk estimation of lung nodules.

read more

Radiation boost lowers risk of prostate cancer recurrence

21 January 2021

An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.

read more

Cognitive behavioral therapy reduces severe fatigue in patients with advanced cancer during treatment

28 January 2020

In Annals of Oncology, RIHS researchers Hanneke Poort, Marlies Peters, Winette van der Graaf, Ria Nijhuis-van der Sanden and colleagues showed significant effects of cognitive behavioral therapy on fatigue in patients with advanced cancer during treatment with palliative intent.

read more

Sarah Verhoeff wins audience award Radboud Talks Jury chose neuroscientist as overall winner

26 March 2019

The winner of the fifth edition of scientific pitch competition Radboud Talks is Suhas Vijayakumar, PhD candidate at the Faculty of Social Sciences and the Donders Institute. Research physician Sarah Verhoeff, Radboud Institute for Health Sciences, won the audience award.

read more

Publication on Salivary duct cancer in the International Journal of Cancer

28 March 2018

Eline Boon and Carla van Herpen described 177 patients with Salivary duct cancer (Rare cancers) with detailed information regarding treatment, outcomes and prognostic factors.

read more

Treatment of rare cancers lags behind

28 February 2018

According to Carla van Herpen in a radio interview on NPO 1 in the context of Rare disease day.

read more